BioSpace News Archive

Vir Biotechnology, Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced the selection of a development candidate (DC) for VIR-2703

PetMed Express, Inc. announced its financial results for its fourth quarter and fiscal year ended March 31, 2020.

Medable, Inc., the leading global platform for decentralized clinical trials, today announced $25 million in funding to accelerate clinical drug development with digital technology, enabling effective new therapies to reach patients faster.

R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-enabled revenue cycle management (RCM) services to healthcare providers, today announced the appointment of Rachel Wilson as Executive Vice President, Chief Financial Officer and Treasurer effective June 1, 2020.

Proprietary low-energy pacing technology offers potential for pain-free cardiac defibrillation with significantly fewer complications and side effects

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that the abstract accepted as an ePoster presentation at Digestive Disease Week (DDW) 2020 Virtual Meeting may now be viewed at the online meeting portal . The ePoster includes preclinical data from the Company’s microbio

Enteris BioPharma, Inc. , a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SW

Correvio Pharma Corp. (“Correvio” or the “Company”) (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has postponed the reporting of its financial statements and management discussion and analysis (the “2020

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, its product candidate for the short-term treatment of the signs

Cerveau Technologies Inc. today announced a research collaboration with University College London (UCL), a leading UK academic center for the production and application of imaging biomarkers for use in clinical research, that grants the institution the right to manufacture [ 18 F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent. The facility has been fully qualified by Cerveau to produce t